NCT04550624View on ClinicalTrials.gov

Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Advanced Biliary Tract Carcinoma
Interventions
DRUG

Pembrolizumab Injection [Keytruda]

200mg IV on day 1 of each cycle

DRUG

Lenvatinib Mesylate

20mg PO daily days 1-21 of each cycle

Trial Locations (2)

200233

NOT_YET_RECRUITING

Shanghai Jiahui International Hospital, Shanghai

RECRUITING

Shanghai Zhongshan Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Zhongshan Hospital

OTHER

lead

Shanghai Jiahui International Hospital

OTHER